Pharmgen Science Inc. (004720) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pharmgen Science Inc. (004720:KRX), powered by AI.

Current Price
₩3,140
P/E Ratio
-0.6
Market Cap
71.1B
Sector
Healthcare
What is the Pharmgen Science Inc. stock price forecast?

Pharmgen Science Inc. is currently trading at ₩3,140. View real-time AI analysis on Alpha Lenz.

What is Pharmgen Science Inc. insider trading activity?

View the latest insider trading data for Pharmgen Science Inc. on Alpha Lenz.

What is Pharmgen Science Inc.'s P/E ratio?

Pharmgen Science Inc.'s P/E ratio is -0.6.

Pharmgen Science Inc.

KRX · 004720
₩3,140+0(+0.00%)Market closedKRX regular session 09:00–15:30 KST
Ask about Pharmgen Science Inc.'s future dividend policy...
Alpha Chat Insight

Pharmgen Science Inc. trades at a P/E of -0.6 (undervalued) with modest ROE of -58.9%.

Ask for details

Company Overview

Pharmgen Science Inc. is a prominent player in the pharmaceutical industry, concentrating on the development, production, and commercialization of a wide array of medicinal products. The company's primary function is to advance medical science and improve healthcare outcomes by discovering new drug compounds and enhancing existing therapies. Pharmgen Science Inc. positions itself at the forefront of biopharmaceutical innovation, engaging in extensive research and development efforts to address unmet medical needs across various therapeutic areas. Notable for its rigorous scientific approach, Pharmgen Science Inc. impacts the healthcare sector significantly by providing cost-effective and efficient pharmaceutical solutions. Its product portfolio may encompass prescription medications, over-the-counter drugs, and possibly biotechnological developments. The company's operations contribute to the broader healthcare landscape, supporting patient health and wellness while also stimulating medical research growth. In the broader market, Pharmgen Science Inc. plays a vital role by partnering with healthcare providers, regulatory agencies, and research institutions to ensure effective distribution and regulatory compliance of its products. With a commitment to innovation and quality, Pharmgen Science Inc. remains a central figure in advancing global healthcare solutions.

CEO김혜연 박희덕(각자)
SectorHealthcare
IndustryDrug Manufacturers - General
Employees226

Company Statistics

FY 2025

Profile

₩71,134,706,100Market Cap
₩173,072,508,290Revenue
22.65MShares Out
226Employees

Margins

64.53%Gross
-83.46%EBITDA
3.46%Operating
-87.31%Pre-Tax
-67.39%Net

Valuation

-0.61P/E
0.49P/B
0.41EV/Sales
-0.38EV/EBITDA
26.84P/FCF

Growth (CAGR)

4.67%Rev 3Yr
12.37%Rev 5Yr
-7.16%Op Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-41.74%ROA
-58.95%ROE
-53.58%ROIC

Financial Health

₩21,880,559,790Cash & Cash Equivalents
₩27,229,044,020Net Debt
33.57%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Pharmgen Science Inc. (ticker: 004720) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - General). It has approximately 226 employees. Market cap is $71.1B.

The current price is ₩3,140 with a P/E ratio of -0.61x and P/B of 0.49x.

ROE is -58.95% and operating margin is 3.46%. Annual revenue is $173.1B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Pharmgen Science Inc. (004720) Stock Forecast 2026 ₩3,140 — Price, Financials & Analyst Targets | Alpha Lenz